Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03506386 · OUTCOME

Duration of Treatment

Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis · Source last updated 2021-02-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
years
Interval / dispersion
Full Range
Time frame
From treatment initiation up to discontinuation of treatment or lost to follow-up, whichever occurs first up to the end of this study (up to 11.7 years)

What was measured

Duration of treatment was defined with respect to selected lines or regimens of interest, considering the time elapsed from each treatment initiation to discontinuation, and censoring participants who lost to follow-up before discontinuation. Duration of treatment was classified by participants eligibility- eligible/not eligible for transplantation. The deaths occurred after treatment initiation to end of study are reported in categories 'Since Diagnosis to Death-Eligible and Not Eligible'.

Analysis population: All participants eligible for analyses who had non-missing observations were analyzed. Number analyzed is the number of participants with data available for given category.

Groups in this outcome

Multiple Myeloma Participants

Participants with MM were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma Participants922

Reported measurements

Since Diagnosis for Living Participants: Eligible

Analysis denominator · Participants

GroupSource count
Multiple Myeloma Participants230
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Multiple Myeloma Participants5Not reported0.611.7Not reported
Since Diagnosis for Living Participants: Not Eligible

Analysis denominator · Participants

GroupSource count
Multiple Myeloma Participants160
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Multiple Myeloma Participants4.2Not reported011.2Not reported
Since Diagnosis to Lost to Follow-up: Eligible

Analysis denominator · Participants

GroupSource count
Multiple Myeloma Participants39
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Multiple Myeloma Participants3.6Not reported08.5Not reported
Since Diagnosis to Lost to Follow-up: Not Eligible

Analysis denominator · Participants

GroupSource count
Multiple Myeloma Participants68
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Multiple Myeloma Participants2.3Not reported0.18.6Not reported
Since Diagnosis to Death: Eligible

Analysis denominator · Participants

GroupSource count
Multiple Myeloma Participants169
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Multiple Myeloma Participants2.8Not reported09.9Not reported
Since Diagnosis to Death: Not Eligible

Analysis denominator · Participants

GroupSource count
Multiple Myeloma Participants256
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Multiple Myeloma Participants1.8Not reported010Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.6
        upper Limit
        11.7
        value
        5
    denoms
    1. counts
      1. group Id
        OG000
        value
        230
      units
      Participants
    title
    Since Diagnosis for Living Participants: Eligible
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        11.2
        value
        4.2
    denoms
    1. counts
      1. group Id
        OG000
        value
        160
      units
      Participants
    title
    Since Diagnosis for Living Participants: Not Eligible
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        8.5
        value
        3.6
    denoms
    1. counts
      1. group Id
        OG000
        value
        39
      units
      Participants
    title
    Since Diagnosis to Lost to Follow-up: Eligible
  4. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.1
        upper Limit
        8.6
        value
        2.3
    denoms
    1. counts
      1. group Id
        OG000
        value
        68
      units
      Participants
    title
    Since Diagnosis to Lost to Follow-up: Not Eligible
  5. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        9.9
        value
        2.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        169
      units
      Participants
    title
    Since Diagnosis to Death: Eligible
  6. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        10
        value
        1.8
    denoms
    1. counts
      1. group Id
        OG000
        value
        256
      units
      Participants
    title
    Since Diagnosis to Death: Not Eligible
denoms
  1. counts
    1. group Id
      OG000
      value
      922
    units
    Participants
description
Duration of treatment was defined with respect to selected lines or regimens of interest, considering the time elapsed from each treatment initiation to discontinuation, and censoring participants who lost to follow-up before discontinuation. Duration of treatment was classified by participants eligibility- eligible/not eligible for transplantation. The deaths occurred after treatment initiation to end of study are reported in categories 'Since Diagnosis to Death-Eligible and Not Eligible'.
dispersion Type
Full Range
groups
  1. description
    Participants with MM were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.
    id
    OG000
    title
    Multiple Myeloma Participants
param Type
MEDIAN
population Description
All participants eligible for analyses who had non-missing observations were analyzed. Number analyzed is the number of participants with data available for given category.
reporting Status
POSTED
time Frame
From treatment initiation up to discontinuation of treatment or lost to follow-up, whichever occurs first up to the end of this study (up to 11.7 years)
title
Duration of Treatment
type
SECONDARY
unit Of Measure
years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice